Karuna Therapeutics (KRTX) is all set for the big day as the Company is scheduled to report results from its phase II clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia on Monday.
from RTT - Biotech https://ift.tt/2Xmgshr
via IFTTT
No comments:
Post a Comment